Background. MicroRNAs are short non-coding regulators of gene expression. The human miR-29 family consists of three members: miR-29a, miR-29b and miR-29c. Members of this family were found to be aberrantly expressed in various types of tumors, including hematological malignancies. This family was described to have both oncogenic and tumor suppressor features influencing various pathological processes, such as tumor growth and apoptosis. This review summarizes current knowledge about the miR-29 family in selected hematological malignancies. Conclusion. Recent research of miR-29 family in hematological malignancies has proven its oncogenic as well as tumor suppressive potential. Nevertheless, the level of current evidence is not sufficient, and data remain inconclusive.
INTRODUCTION
MicroRNAs (miRNAs) are short, non-coding and highly conserved RNAs, approximately 22 bp in size 1 . The genes for miRNAs represent 1-2% of all known eukaryotic genes 2 . They regulate gene expression, both at transcriptional and translational levels. A single miRNA molecule can control expression of various genes and vice versa, one gene can be regulated by various miRNAs 3 . MiRNAs act in a wide range of physiological biological processes, such as cell proliferation, differentiation, apoptosis and hematopoiesis [4] [5] [6] . As all of these processes, as well as miRNAs levels, are dysregulated in solid tumors and hematological malignancies, it was confirmed that there is an association between miRNAs and cancer 7 . Despite the fact that miRNAs were discovered in 1993 (ref. 8 ), it was only in 2002 that miR-15a and miR-16-1 were identified as potential cancer genes in the pathogenesis of chronic lymphocytic leukemia (CLL) highlighting the direct link between miRNAs deregulation and hematological malignancy 9 . Genes for miRNA are frequently located at fragile sites and genomic regions involved in cancers, such as minimal regions of loss of heterozygosity, minimal regions of amplification (minimal amplicons), or common breakpoint regions, explaining the contribution of miRNAs to cancerogenesis 10 . Such localization may lead to upregulation of miRNAs levels or their downregulation during pathological processes. Further, depending on the mRNA target which miRNAs bind and regulate, they can act either as oncogenes (also called oncomirs) or as tumor suppressors 11 . Due to overexpression of miRNA targeting tumor suppressor gene, anti-oncogenic mechanisms can be inhibited, whereas defects of miRNA repressing oncogene can lead to gain of oncogenic features. Both these roles have been demonstrated in tumors [12] [13] [14] . In general, miRNAs can affect specific cell development (e.g. B cell) or alter expression of components in miRNA biogenesis in hematological malignancies.
Canonical model of the miRNAs biosynthetic pathway involves several steps as shown in Fig. 1 . In the nucleus, RNA polymerase II transcribes miRNA genes into long primary precursors -pri-miRNAs. These are recognized and cleaved by microprocessor complex including ribonuclease Drosha and dsRNA-binding protein Pasha (or DGCR8) (ref. 15, 16 ). Secondary precursors are short, about 70 nucleotides stem-loop structures, known as pre-miRNAs that are further actively transported to cytoplasm by exportins, Ran-GTP dependent transporters. In the cytoplasm, pre-miRNAs are processed near the terminal loop by RNase III type endonuclease Dicer, which is in complex with dsRNA-binding protein TRBP (TAR RNA binding protein), and this generates mature miRNA/ miRNA* duplexes 17, 18 . Subsequently, one strand of mature miRNA (so-called guide strand), which is less stable at the duplex 5'end, is incorporated into the Argonaut protein, a central part of multiprotein complex miRISC (miRNAinduced silencing complex). The other strand, called the passenger strand (miRNA*), is released from the duplex and degraded. The question of gene fate now lies in the RISC complex with incorporated mature miRNA because this is the site where gene mRNA and miRNA pair. If the complementarity between the seed sequence of miRNA (2-8 nucleotides at 5'end) and the 3'UTR of the target mRNA is perfect, mRNA is cleaved and degraded. In the other case, low degree of complementarity leads to inhibition of mRNA translation ( Fig. 1 ) (ref. 19 ).
THE MIR-29 FAMILY
In the human miR-29 family, the precursors are transcribed into two clusters, miR-29a/miR-29b-1 from chromosome region 7q32, and miR-29b-2/miR-29c from chromosome region 1q32. As the only difference between miR-29b-1 and miR-29b-2 is their localization in different parts of genome, they both form identical mature miR29b. The first discovered member of the family was miR29a in HeLa cells in 2001 (ref. 20 ), followed by miR-29b and miR-29c (ref. 21, 22 ). The members of the miR-29 family have identical seed sequence, similar expression patterns as well as function. The only differences among miR-29 members were reported in their expression levels in various cancerous tissues as some studies claim that miR-29a or miR-29c do not follow the same expression pattern as miR-29b (ref. 23 ). It was described that in lung cancer, only miR-29b-2 was differentially expressed 24 . Further, miR-29b was found to be differentially expressed in cholangiocytes and in brain malignancies 25, 26 . Another study demonstrated that expression of miR-29a and miR-29c in cervical cancer was decreased 27 . These results suggest that miR-29 is not tissue-specific.
MIR-29 UNDER PHYSIOLOGICAL CONDITIONS
The miR-29 family regulates several signaling pathways that are involved in various physiological and pathological processes. Physiologically, it takes part in regulation of cell cycle and proliferation [27] [28] [29] [30] , senescence 31, 32 , differentiation 33, 34 , apoptosis 25, 28, 30, 35, 36 , metastasis 37, 38 , DNA methylation [39] [40] [41] and immune regulation 42, 43 , as well as regulation of extracellular matrix (ECM).
MiR-29 in cell cycle, proliferation and differentiation
Progression through the eukaryotic cell cycle is driven by cyclin-dependent kinases (CDKs), which are regulated by interaction with oscillatory expressed proteins called cyclins 44 . In cell cycle progression, from G1 to S phase, cyclin D1 binds CDK6 and CDK4 which then phosphorylate and inactivate Rb protein. These CDKs are essential for response to mitogenic stimuli, therefore the loss of CDK6 affects production of terminally differentiated cells ( Fig. 2 ) (ref. 45 ). It was demonstrated that 3'UTR of CDK6 contains 2 conserved sequence motifs with perfect homology to miR-29 seed sequence; therefore, CDK6 was suggested as a direct target of miR-29 (ref. 29 ).
In terms of its role in cell differentiation, miR-29b has multiple functions in osteoblastogenesis -to control collagen expression during ECM maturation is one of them. However, this process does not happen in immature cells. Instead, miR-29b helps to maintain the differentiated phenotype in osteoblasts through regulating collagen. On the other hand, miR-29b downregulates negative regulators of signaling pathways to promote osteoblastogenesis. Both these miR-29b roles regulate osteoblast differentiation 46 .
In another study, miR-29a and miR-29c were shown to be induced by the Wnt pathway that is critical in osteoblast differentiation. During the late phases of osteoblast differentiation, the expression of these miRNAs is upregulated and increased. Beside this, miR-29a and miR-29c downregulate osteoblast differentiation by targeting osteonectin, an essential protein for bone remodeling 33 . Apart from osteoblast differentiation, miR-29 was reported to play a role in muscle cells development. The miR-29 family enhances myogenic differentiation through its involvement in the NF-κB-YY1 regulatory loop. In myogenesis, downregulated transcription factors NF-κB and Yin Yang 1 (YY1) decrease miR-29 levels and this in turn induces differentiation by targeting YY1 (ref. 34 ). Another experiment showed that miR-29 together with miR-142 also regulates monocytic and granulocytic (myeloid) differentiation. Targeting CDK6 by miR-29, as well as targeting cyclin T2 (CCNT2), a component of positive transcription elongation factor b (P-TEFb), by either miR-29 or miR-142 increases myeloid differentiation 47 .
Aging processes and senescence
MiR-29 might be a pro-aging miRNA as it accumulates during aging and its upregulation is associated with DNA damage response. MiR-29 is part of the signaling pathway involving Ppm1d/Wip1 phosphatase, a key DNA damage response regulator, and the p53 tumor suppressor (Fig. 3) (ref. 31 ). Further effects of miR-29 during cellular senescence were described in association with B-Myb which is an oncogene and a transcription factor for various genes involved in proliferation 48 . Besides these functions, B-Myb is able to induce senescence by inhibition of its transcription 49 . One of the options for repressing abundant B-Myb mRNA is through binding of Rb-E2F complexes to B-Myb promoter 50 . The other option of B-Myb repression at the posttranscriptional level involves miRNAs. MiR-29 together with miR-30 directly targets B-Myb 3'UTR and reduce its expression in cells undergoing senescence 32 . These facts are also consistent with miR-29 suppressor function in cancer.
ECM regulation
ECM regulation includes formation of extracellular matrix key proteins, e.g. various collagen (COL) isoforms, elastins, metalloproteinases, etc (ref. 23, 46 ). In osteoblasts, miR-29 regulates essential proteins of bone ECM. It mediates translational inhibition and decreases COL1A1, COL5A3, COL4A2 synthesis; furthermore, it maintains differentiated phenotype in mature cells 46 . The broad spectrum of collagens and other related genes, e.g. matrix metallopeptidase 2, which are miR-29 targets, was confirmed and even extended in a study done on rats. There were 20 genes for collagen predicted as miR-29 targets which makes this miRNA unique because no other miRNA targeted more than 11 collagen genes 23 . Regulation of these proteins by miR-29 is implicated in the development of fibrosis in many organs [51] [52] [53] and systemic sclerosis 54 . Not only in mice developing liver fibrosis, but also in patients with hepatic fibrosis, the miR-29 family was significantly downregulated and inhibited collagen expression in hepatic stellate cells 52 . A significant decrease was also found in the lungs of idiopathic pulmonary fibrosis patients 53 .
MIR-29 IN HEMATOLOGICAL MALIGNANCIES
Despite the range of physiological processes the miR-29 family is involved in, most studies concentrate on its pathological function and tumor suppressive or oncomir (oncogenic miRNA) effects in various cancers. In terms of solid tumors and hematological malignancies, both these roles have been proven; they are believed to depend on cellular context or tissue specificity. Although expression of miR-29 was found to be altered in cancer, its role in pathogenesis of hematological malignancies is still poorly understood 55 . There is, however, a predominance of publications supporting the tumor suppressor role of the miR-29 family. By targeting oncogenes, the miR-29 family helps prevent carcinogenesis; therefore, in cancer, its levels are downregulated (Table 1 ) (ref. 12, 56, 57 ). Furthermore, it was observed that miR-29 is associated with some cytogenetic aberrations. MiR-29, among other miRNAs, was found to be down-regulated in acute myeloid leukemia (AML) patients with 11q23 balanced translocation compared to AML patients without this translocation 56 . Further, Garzon et al. observed that miR29a and miR-29b are downregulated in primary AML samples with monosomy of chromosome 7. However, forced expression of these miRNAs had first anti-proliferative effects and later anti-apoptotic effects in AML cell lines and primary AML blasts, thus inhibiting cell growth and induced apoptosis by targeting Mcl-1 (Myeloid cell leukemia-1) (ref. 28 ). In AML patients with monosomy of chromosome 7 or deletion of 7q, a link between miR-29a and oncogene Ski was described as the nuclear oncogene Ski is upregulated and miR-29a located on 7q32 is downregulated in these AML patients. Further, it was shown that miR-29a targets Ski, as their expression is inversely correlated, which suggest the tumor suppressive role of miR-29a (ref. 58 ). Although previous study reported also tumor suppressor miR-29 family to be upregulated in AML patients with mutations in the nucleophosmin (NPM) gene when compared to wild type NPM (ref.
59
); however, this was not confirmed and miR-29 downregulation was described in AML patients independently of the NPM status 60 . A genome-wide profiling study on CLL (chronic lymphocytic leukemia) revealed that miR-29 precursors are upregulated 61 . Afterwards, another study demonstrated downregulated miR-29a in aggressive CLL compared to indolent CLL (ref. 35 ). Interestingly, miR-29a was found to be the second and miR-29c the fifth most represented miRNA among the most expressed miRNAs in CLL (ref. Despite some knowledge about miR-29 in other hematological malignancies, little is known about this miRNA in mantle cell lymphoma (MCL) and further research in this field is needed. One report showed notably decreased miR-29 levels in MCL patients, which were associated with higher levels of its target CDK6 and with shorter overall survival of MCL patients. Therefore, the use of miR-29 as a prognostic marker and pathogenetic factor in MCL was suggested 29 . Besides studying direct miR-29 family effects and its participation in regulation, there is an effort to apply miR-29 as novel biomarkers. The analysis of miR-29a together with miR-142-3p indicated that these miRNAs could be used as AML molecular diagnostic markers. Because of their key role in regulation of normal myeloid differentiation, miR-29a and miR-142-3p abnormal expression was shown to be involved in AML development, as it directly affected target genes important in AML (ref. 60 ). Recently, the first evidence of miR-29a as an unfavorable prognostic marker in AML was indicated, as downregulation of miR29a was shown to be associated with advanced clinical features and poor prognosis in pediatric AML patients 63 .
Apoptosis in hematological malignancies
Majority of studies show that miR-29 family effects in cancer are anti-apoptotic. However, in studied hematological malignancies, the miR-29 levels were lower than in physiological conditions. Therefore the tumor suppressive impact of miR-29 on cancer cells is poor (Table 1) . MiR-29 family was described to target genes involved in regulation of apoptosis, such as Bcl-2 (B-cell leukemia/ lymphoma) family members and a key anti-apoptotic protein Mcl-1 that are often dysregulated in malignant cells (Table 2 ). Constitutive Mcl-1 expression can cause malignant transformation as was demonstrated in transgenic mice 64 . MiR-29b negatively regulates Mcl-1 protein expression; low miR-29b levels upregulate Mcl-1 expression and thus induce anti-apoptotic signals and may play a role in tumor development. On the other hand, experiments with enforced miR-29b expression showed sensitivity to cell death which might be valuable in cancer therapy 25 .
In multiple myeloma (MM), a plasma cell malignancy, the miR-29b tumor suppressor effects are implicated as well. It was shown that miR-29b is downregulated in MM; however, its overexpression can downregulate Mcl-1 expression and is associated with caspase-3 activation. By targeting critical oncogenic pathways, miR-29b inhibits growth and induces apoptosis of MM cells 12 . Another miR-29 family target is Tcl1 (T-cell leukemia/ lymphoma 1) gene), a significant oncogene involved in CLL pathogenesis. Tcl1 operates as a coactivator of the Akt oncoprotein that is important in the anti-apoptotic pathway in B-and T-cells 65, 66 . Pekarsky et al. demonstrated that miR-29 family members are partly natural Tcl1 inhibitors and that downregulated miR-29 levels in aggressive CLL might be a causal event in disease pathogenesis 35 . Another study suggested that the downregulation of miR-29 upregulates Tcl1 in aggressive CLL, and thus develops aggressive phenotype 14 . Amodio et al. recently identified new miR-29b target Sp1, a transcription factor that participates in cell cycle regulation and apoptosis 67 . In MM, Sp1 is involved in cell survival and promotes MM cell growth 68 . Sp1 is downregulated by miR-29 but it was demonstrated that the forced expression of miR-29b in cell lines inhibited cell growth and triggered apoptosis in vitro and in vivo in a murine model. Besides this, miR-29b-Sp1 regulatory loop was described. Not only miR-29b influences Sp1 but also Sp1 negatively regulates miR-29b. Upregulated Sp1 transcriptionally inhibits miR-29b and silenced Sp1 increases miR-29b levels. All of this may prevent the tumor formation in a model of MM (ref. 67 ). A study done by Garzon et al. describes the effects of miR-29 on both apoptosis and proliferation in AML cells. The forced expression of miR-29a and miR-29b led to cell growth inhibition and induction of apoptosis. After the transfection of the miRNAs, the first observed effect was inhibition of apoptosis. It was confirmed that Mcl-1 and other anti-apoptotic genes are miR-29 targets and that this miRNA also upregulates proapoptotic genes. The anti-proliferative effect was observed later after the transfection, which means that the miR-29-dependent pro- 28 .
Tumor initiation and growth
Although tumor suppressor effect of miR-29a was elucidated, some studies show that the miR-29 family has also tumor promoting effects, but this oncomir function still remains poorly understood. The first example of a miRNA initiating AML in vivo was reported by Han et al. They showed that miR-29a was highly expressed in human AML and its overexpression led to higher incidence of AML. MiR-29a can induce AML by converting myeloid progenitors into self-renewing leukemia stem cells, thus showing oncogenic potential 13 . The same was demonstrated in CLL where miR-29a was overexpressed in indolent CLL in comparison to normal B cells. However, a hypothesis of solely miR-29 initiating leukemia was not confirmed 14 . As for MM, one of its main characteristics is bone disease which is a result of imbalance between osteoblasts and osteoclasts bone formation caused by MM cells. It was found that miR-29b expression decreases during osteoclast differentiation in vitro and suppresses its targets c-Fos and metalloproteinase 2. miR-29b-based treatment of MM-related disease was suggested when the results showed enforced miR-29b expression disrupting osteoclast differentiation and overcoming osteoclast activation 69 .
CIRCULATING MIR-29
In 2008, the discovery of miRNA present in body fluids was reported. MiRNAs were found in almost all body fluids, e.g. serum, plasma, saliva, urine, etc (ref. [70] [71] [72] [73] ). Interestingly, under unfavorable conditions, such as boiling, storage at room temperature, low or high pH or repeated cycles of freeze-thawing, plasma miRNAs were found to be unconventionally stable. Possibly, there are two mechanisms by which circulating miRNAs are protected from degradation. The first possibility is to form ribonucloeprotein complexes of miRNA and RNA-binding protein, e.g. Ago2 (ref. 74 ), NPM-1 (ref. 75 ) or high-density lipoproteins (HDLs) (ref. 76 ). The other option is packaging in small vesicles. Depending on the size and form of release, these small vesicles can be exosomes, which are released from endosome membrane, or microvesicles, that are shed directly from plasma membrane, or even apoptotic bodies [77] [78] [79] [80] . Current evidence shows that the majority of circulating miRNAs are bound to proteins rather than found in vesicles. This aside, it seems that cells can actively select which miRNAs will be released from cells and which will stay within the cell 81 . However, little is known about circulating miRNA origins and factors in their regulation and other underlying mechanisms need to be determined.
Our own data showed the presence of circulating serum miR-29a in MM patients. Serum levels of miR29a were able to distinguish MM patients from healthy donors. Although further analysis is required, it is possible that circulating miRNAs represent a novel and easily accessible putative marker 82 . Such a marker would be important and highly clinically relevant in diseases such as MM, where frequent testing of bone marrow is not ethically permissible.
The question of comparing established biomarkers and circulating miRNAs was investigated in patients with CLL (ref. 83 ). A set of 3 miRNAs, including miR29a, was able to distinguish healthy controls from CLL patients. Furthermore, another set of miRNAs, including miR-29a, was compared with IgV H and zeta-associated protein (ZAP) status, an established clinical risk stratifier in CLL (ref. 84 ). This miRNA set could separate ZAP-70 + and ZAP-70 -samples but did not correlate with IgV H mutation status 83 .
CONCLUSION
First dismissed as a type of junk RNA, miRNAs were demonstrated to be pivotal in gene regulation. In recent years, miRNAs have also been discovered to be important players in cancer pathogenesis and understanding of their significance has broadened. MiRNAs function both as tumor suppressors and oncomirs.
MiR-29 is involved in various physiological processes, such as proliferation, differentiation, apoptosis and senescence. It has also been shown that the miR-29 family is deregulated in hematological malignancies as well as in solid tumors. The analyses are influenced by heterogeneity of the diseases, detection methods used, various genetic background of patients/control groups, and different disease stage. In some cases, small data sets may impair data validation. However, its specific role in hematological malignancies remains unclear.
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